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A Second Leaky Splice-Site Mutation in the Spastin
Gene
To the Editor:
Mutations in the gene encoding spastin, an ATPase of
unknown function, cause the most common form of au-
tosomal dominant hereditary spastic paraplegia (SPG4
[MIM 182601]; Hazan et al. 1999), a neurodegenerative
disorder characterized by progressive spasticity of the
lower limbs. Recently, we described 11 mutations in this
gene, 7 of which cause missplicing of the spastin tran-
script (Svenson et al. 2001). Because of the presence of
a rare spastin gene–coding region polymorphism in the
proband of one family with an IVS94arg mutation in
the spastin gene, we were able to determine that this
mutation is only partially penetrant—that is, both nor-
mally and aberrantly spliced (skipped exon 9) transcripts
are produced from the mutant allele. This “leakiness”
of the mutation was not recapitulated in in vitro splicing
experiments with minigene constructs containing only
exon 9 and flanking intronic sequence. However, when
we included additional sequence (exons 8–12, with
flanking intronic sequence), the leakiness of the mutation
was recapitulated. These findings demonstrate the im-
portance of genomic-sequence context in the determi-
nation of splice-site selection and the extent of missplic-
ing caused by this mutation.
Because of the absence of any other spastin gene–coding
region polymorphisms, we were unable to test several
other splice-site mutations for leakiness by reverse-tran-
scriptase (RT)–PCR analysis of patient-derived RNA.
None of these other mutations appeared leaky in our in
vitro splicing experiments with minigene constructs, even
in the larger genomic-sequence context that included
flanking exons.
We have since found that at least one of these other
splice-site mutations is, in fact, leaky in a much larger
genomic-sequence context—that is, in the complete hu-
man chromosome 2 that harbors the mutation. This mu-
tation, an IVS112t insertion, causes skipping of exon
11, as determined by RT-PCR analysis of patient-derived
RNA (see the report by Svenson et al. [2001], for ped-
igree information and experimental data). In our in vitro
splicing experiments with a minigene construct that car-
ries this mutation as well as the complete sequence
of both flanking introns and exons on each side of
the skipped exon, we detected only aberrantly spliced
(skipped exon 11) transcript (fig. 1A). To determine
whether the presence of additional genomic-sequence
context would affect the change in splice-site selection
caused by this mutation, we performed RT-PCR analysis
of RNA extracted from mouse-human hybrid cell lines
containing either the wild-type or the mutant chromo-
some 2 of a patient with SPG who is heterozygous for
this mutation. As shown in figure 1B, we detected both
normally and aberrantly spliced transcripts in the RNA
extracted from the hybrid cell line containing the mu-
tant—but not the wild-type—chromosome 2. We con-
firmed through sequencing that the transcripts were de-
rived from the human and not the mouse spastin gene.
We were unable to test the other splice-site mutations
for leakiness by this method, because of the lack of avail-
ability of appropriate patient-derived cell lines.
These findings provide further evidence of the depen-
dence of splice-site selection on genomic-sequence con-
text. The exon-definition model of splice-site selection
proposes that an exon is defined by the binding of splicing
factors to the 3′ and 5′ splice sites of the same exon (Berget
1995). Pairing of U1 small nuclear RNA (snRNA) to the
5′ splice junction includes at least six nucleotides beyond
the invariant gt. The IVS112t insertion mutation would
shift the base pairing by one nucleotide, resulting in a net
loss of four base pairs relative to the pairing with the
wild-type sequence. Despite this drastic alteration in U1
snRNA:hnRNA (i.e., heterogeneous nuclear RNA) pair-
ing, this mutation, in its full genomic-sequence context,
is only partially penetrant.
Given these observations, we suggest that, in the case
of splicing mutations outside the invariant gt–ag splice-
site sequences, splice-site selection might also depend on
the definition of exons and the strength of intron-exon
junction sequences not directly adjacent to the mutant
splice junction. In addition, splice-site selection might be
influenced, in part, by intronic sequences distant from
the intron-exon junctions.
Although the function and normal range of expression
level of spastin are still unknown, our findings reported
here provide additional support for the hypothesis that
the function of spastin is highly concentration depen-
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Figure 1 A, The pSPL3 exon-trapping vector was used to assay splice-site selection. COS1 cells were transfected with vector alone (pSPL3),
with wild-type exons 10–12 and flanking intronic sequence (wild type), or with the same construct but containing the IVS112t insertion
(mutant). Top panel, Schematic showing construct design, vector-specific primers used for amplification (horizontal arrows), site of mutation
(vertical arrow), and splice variants a, b, and c. Bottom panel, Transcripts identified on the basis of sequencing of the correspondingly labeled
RT-PCR products (a, b, and c). B, RT-PCR analysis of RNA extracted from a lymphoblastoid cell line from a normal control individual (control),
from a patient heterozygous for the IVS112t insertion (2187), or from a mouse E2-human hybrid cell line hemizygous for human chromosome
2, without (wild type) or with (mutant) the IVS112t insertion. Top panel, Schematic showing positions of primers used for amplification
(horizontal arrows), site of mutation (vertical arrow), and splice variants a and b. Bottom panel, Transcripts identified on the basis of sequencing
of the correspondingly labeled RT-PCR products (a and b).
dent. Our finding that normally spliced transcript is pro-
duced from at least two different mutant alleles is con-
sistent with the threshold of spastin required for
transition from normal function to disease state lying
within a narrower interval than the 50% decrease pre-
dicted by a disease model of haploinsufficiency. Thus,
as we have speculated elsewhere (Svenson et al. 2001),
even slight variation in spastin expression level might
have dramatic phenotypic consequences, accounting, at
least in part, for the wide variability in age at onset,
symptom severity, and rate of symptom progression re-
ported to occur in SPG caused by spastin gene mutations.
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